Table 2.
The demographic and clinical characteristics before treatment in the four groups.
| Character | Control group | Single-allergen group | 1- to 2-allergen group | ≥3 allergen group | p-value |
|---|---|---|---|---|---|
| Case No. | 37 | 35 | 32 | 29 | p > 0.05 |
| Male | 10 | 16 | 8 | 13 | p > 0.05 |
| Female | 27 | 19 | 24 | 16 | p > 0.05 |
| Age (years) | 42.16 ± 11.10 | 39.49 ± 11.60 | 41.88 ± 11.29 | 36.97 ± 10.25 | All p > 0.05 |
| TASS | 5.35 ± 1.21 | 5.06 ± 1.37 | 4.78 ± 1.29 | 5.03 ± 1.35 | All p > 0.05 |
| TAMS | 7.60 ± 1.01 | 7.86 ± 1.42 | 7.31 ± 1.89 | 7.55 ± 1.64 | All p > 0.05 |
| ACT | 14.73 ± 2.24 | 15.37 ± 2.37 | 14.97 ± 2.44 | 14.00 ± 2.02 | All p > 0.05 |
| FEV1/FVC% | 76.80 ± 5.54 | 73.65 ± 5.64 | 76.23 ± 4.95 | 75.13 ± 3.85 |
p < 0.05 (Single vs. Control/1–2) |
TASS, total asthma symptom score; TAMS, total asthma medicine score; ACT, asthma control test; FEV1/FVC%, forced expiratory volume in 1 s/forced vital capacity.